FDA Approves Pembrolizumab Plus Paclitaxel With/Without Bevacizumab for PD-L1+ Platinum-Resistant Ovarian Cancer | OncLive The FDA approved pembrolizumab with paclitaxel ± bevacizumab for PD-L1–positive platinum-resistant ovarian cancer, with a companion diagnostic.

BREAKING 🚨: @fda.gov Approves Pembrolizumab Plus Paclitaxel +/- Bevacizumab for PD-L1+ PROC #ovca #gynsm #FDAapproved

Read more 📰: www.onclive.com/view/fda-app...

Dana Chase, MD, Maurie Markman, MD, and Robert Neff, MD, detail the current state of HPV vaccination and screening during #CervicalCancerAwarenessMonth

Sign up and read their exclusive insights #gynsm #oncology www.onclive.com/view/hpv-vac...

Vicky Makker, MD, Antonio Gonzalez-Martin, MD,
Dana Chase, MD, and Vanda Salutari, MD, highlight some of the top data in gynecologic oncology presented at #ESMO25

Watch and read their exclusive insights! #ovca #gynsm

www.onclive.com/view/emergin...

Lots of exciting data at #ESMO25. Here are the 3 Presidential Symposia presentations. Tomorrow: DESTINY-Breast11 (high-risk HER2+ eBC), DESTINY-Breast05 (high-risk HER2+), KEYNOTE-05 (MIBC), KEYNOTE-B96 (ovarian). #BCSM #Bladdercancer #gusm #ovariancancer #gynsm

PICCOLO: final analysis of mirvetuximab soravtansine in ovarian cancer - VJOncology Angeles Secord, MD, Duke Cancer Institute, Durham, NC, discusses the final analysis of the Phase II PICCOLO study (NCT05041257), which...

🎥 Angeles Secord, MD, of @dukecancer.bsky.social shares final Phase II PICCOLO results: mirvetuximab soravtansine shows durable responses & good survival in FRα+ platinum-sensitive ovarian cancer:

➡️https://buff.ly/ysRSWzX⬅️

@ascocancer.bsky.social #ASCO25 #GynOnc #GynSM #TrialUpdate #CTSM

Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer Extended follow-up showed sintilimab plus anlotinib yielded durable efficacy and tolerability in PD-L1–positive recurrent/metastatic cervical cancer.

Sintilimab Plus Anlotinib Shows Durability in PD-L1+ Recurrent/Metastatic Cervical Cancer #gynsm #oncology www.onclive.com/view/sintili...

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer @ascocancer.bsky.social #ASCO25 #gynsm #oncology www.onclive.com/view/explora...

Just spoke with Alexander Olawaiye, MD, of UPMC Hillman Cancer Center, about the ROSELLA trial evaluating relacorilant plus nab-paclitaxel in platinum-resistant ovarian cancer. Keep an eye out for more key takeaways from this study! @ascocancer.bsky.social #ASCO25 #gynsm

There are multiple points along the #cancertreatment pathway where a #secondopinion is an important option. Click below to register for the @PinkRibbonGood webinar, Beyond Diagnosis: The Power of a 2nd Opinion this Thursday, May 8, 12-1pmET:
bit.ly/4iMHaHS

#BCSM #GYNSM #MEDSKY

PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer #SGO25 #ovca #gynsm www.onclive.com/view/parp-in...

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer #SGO2025 #gynsm #oncology www.onclive.com/view/dual-pd...

Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer #gynsm #oncology www.onclive.com/view/tisotum...

"Matt Hellmann [VP Early Oncology Dev] told @endpts.com
in interview that there have been very few advances in 2nd-line endometrial cancer over the past several decades. For context, chemotherapy currently produces a response rate in the 20% range & a PFS of 4 to 5 months, he said" #gynsm #SGO2025

AstraZeneca reveals first-in-human data for B7-H4-targeting ADC in endometrial cancer AstraZeneca is fine-tuning plans for a Phase 3 study for its B7-H4-targeting ADC after the drug produced encouraging response and survival results in endometrial cancer patients enrolled in an early s...

The 2.4 mg/kg dose hit a 38.5% ORR, according to data presented Saturday at the Society of Gynecologic Oncology’s annual meeting on women’s cancer in Seattle. #SGO2025 #gynsm endpts.com/astrazeneca-...

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer Puxitatug samrotecan demonstrated preliminary efficacy and manageable safety in advanced or metastatic endometrial cancer.

Puxitatug Samrotecan Demonstrates Efficacy, Manageable Safety in Advanced/Metastatic Endometrial Cancer #SGOMtg #SGO25 #gynsm #oncology www.onclive.com/view/puxitat...

We’re diving into our first full day of #SGO2025, starting with this morning's plenary session on maximizing therapeutic benefit through targeted strategies and predictive assays.

Want to share your expert take? Contact us to schedule an interview! #SGOMtg #gynsm

Good morning Seattle! 🌆

☔ Rain or shine, we're ready to kick off our live coverage of #SGO2025! From expert-led sessions to cutting-edge research, we’ll be sharing all the latest updates in gynecologic oncology. You won't want to miss it!

#SGOMtg #AM25IMPACT #gynsm

Tonight at 7:30pm #YaleCancerAnswers host Dr. Eric Winer talks with #gynoncologist Dr. Elena Ratner about the use of #roboticsurgery to treat #gynecolociccancers.
🎧 Listen live- WNPR
🔁 Download- Apple Podcasts
💻 Watch- YouTube
#gynsm
@yaleschoolofmed.bsky.social

FDA Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer The ACR-368 OncoSignature assay has received breakthrough device designation from the FDA for use in endometrial cancer.

The @fda.gov Grants Breakthrough Device Designation to ACR-368 OncoSignature Assay for Endometrial Cancer #gynsm #oncology www.onclive.com/view/fda-gra...

Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer #SGOmtg #ovca #gynsm www.onclive.com/view/trend-t...

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer The addition of chemotherapy to radiation therapy following surgery conferred a benefit in certain endometrial cancer molecular subtypes.

Molecular Subtyping Predicts Recurrence and Survival Benefits in Endometrial Cancer
#SGOmtg #gynsm #oncology
www.onclive.com/view/molecul...

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer An observational cohort study determined that discordance exists between p53 protein expression and TP53 mutation status in high-risk endometrial cancer.

Observational Data Challenge p53 Expression as a Surrogate Marker for TP53 Mutations in High-Risk Endometrial Cancer #SGOmtg #gynsm #oncology www.onclive.com/view/observa...

ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer Anetumab ravtansine plus bevacizumab failed to improve efficacy vs paclitaxel plus bevacizumab in platinum-resistant high-grade ovarian cancer.

ADC Anetumab Ravtansine Does Not Improve PFS vs Paclitaxel in High-Grade Serous Ovarian Cancer #ovca #gynsm #oncology www.onclive.com/view/adc-ane...

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer Frontline dostarlimab plus chemotherapy has been approved in the EU for all adult patients with primary advanced or recurrent endometrial cancer.

European Commission Approves Dostarlimab Plus Chemo for All Advanced/Recurrent Endometrial Cancer #gynsm #oncology www.onclive.com/view/europea...

Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of Mirvetuximab Soravtansine in Ovarian Cancer Ritu Salani, MD, discusses the role of mirvetuximab soravtansine in ovarian cancer and the need for specialist involvement in ocular toxicity management.

Ocular Toxicity Management and Early FRα Testing Are Key to Maximizing Efficacy of Mirvetuximab Soravtansine in Ovarian Cancer
#gynsm #oncology #MedEd #MedTwitter
www.onclive.com/view/ocular-...

Draft Evidence Review: Cervical Cancer: Screening | United States Preventive Services TaskforceShare to FacebookShare to XShare to WhatsAppShare to EmailPrint

USPSTF issues draft guidance for cervical cancer screening that include a self collection option. #gynsm #oncsky www.uspreventiveservicestaskforce.org/uspstf/docum...

Covid doesn't care about cancer | Bonfire but METAvivor does! We raised $4.4 MILLION for metastatic...

here you go @kkbadger1 and anyone else with #cancer or a #chronicillness who might want a G-rated #VaccinatedButVulnerable shirt - more styles and colors added. Proceeds to @metavivor. #bcsm #lcsm #crcsm #btsm #gynsm
https://www.bonfire.com/vaccinated-but-vulnerable/

The #VaccinatedButVulnerable, salty version, has been updated with new styles and colors, per request (@silke4senate 😉). #CovidVaccine #MaskUp #bcsm #lcsm #btsm #gynsm #crcsm #cancer #chronicillness. All proceeds benefit @metavivor ...

I’ve just been notified I will be given 3 minutes during the public comment section of the upcoming virtual CDC ACIP meeting to talk about why people w/ active #cancer should be moved up in #COVID19Vaccine priority list. #bcsm #lcsm #crcsm #gynsm #btsm drop your links to data!

Access to this page has been denied px-captcha

Once again, patients are getting screwed. #biosimilars @P4AD_ #bcsm #lcsm #btsm #crcsm #gynsm

www.sfchronicle.com/business/article/Future-...